Raymond James Financial’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Raymond James Financial’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.55M	Sell	75,462 -1,148	-1%	-$34.4K	﹤0.01%	3314
2026 Q1	$2.23M	Sell	76,610 -63,814	-45%	-$1.85M	﹤0.01%	3275
2025 Q4	$3.68M	Sell	140,424 -7,683	-5%	-$198K	﹤0.01%	2753
2025 Q3	$3.5M	Buy	148,107 +12,552	+9%	+$278K	﹤0.01%	2732
2025 Q2	$2.78M	Buy	135,555 +10,314	+8%	+$208K	﹤0.01%	2813
2025 Q1	$2.57M	Buy	125,241 +96,973	+343%	+$2.16M	﹤0.01%	2818
2024 Q4	$640K	Buy	+28,268	New	+$679K	﹤0.01%	3752

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's IDNA Position: Q2 2026 in Review

Raymond James Financial reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 1.5% in Q2 2026, selling an estimated $34.4K and leaving 75,462 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3314.

Raymond James Financial first reported a position in IDNA in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.68M in Q4 2025. 65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Raymond James Financial held 75,462 shares of iShares Genomics Immunology and Healthcare ETF worth $2.55M as of Q2 2026.
Raymond James Financial sold 1,148 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $34.4K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3314 holding.
Raymond James Financial first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's iShares Genomics Immunology and Healthcare ETF position peaked at $3.68M in Q4 2025.
65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.